BRPI0520258A2 - use of a pharmaceutical composition, method for preparing a pharmaceutical composition, and use of an effective amount of eslicarbazepine acetate - Google Patents

use of a pharmaceutical composition, method for preparing a pharmaceutical composition, and use of an effective amount of eslicarbazepine acetate

Info

Publication number
BRPI0520258A2
BRPI0520258A2 BRPI0520258-2A BRPI0520258A BRPI0520258A2 BR PI0520258 A2 BRPI0520258 A2 BR PI0520258A2 BR PI0520258 A BRPI0520258 A BR PI0520258A BR PI0520258 A2 BRPI0520258 A2 BR PI0520258A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
preparing
eslicarbazepine acetate
effective amount
present disclosure
Prior art date
Application number
BRPI0520258-2A
Other languages
Portuguese (pt)
Inventor
Jose Luiz Almeida
Silva Patricio Manuel Vieira Araujo Soares Da
Original Assignee
Portela & Ca Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portela & Ca Sa filed Critical Portela & Ca Sa
Publication of BRPI0520258A2 publication Critical patent/BRPI0520258A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Abstract

USO DE UMA COMPOSIçãO FARMACêUTICA, MéTODO PARA PREPARAR UMA COMPOSIçãO FARMACêUTICA, E, USO DE UMA QUANTIDADE EFICAZ DE ACETATO DE ESLICARBAZEPINA. A presente descrição refere-se ao tratamento de várias doenças e condições com acetato de eslicarbazepina. A presente descrição também refere-se ao uso de acetato de eslicarbazepina em um método para reduzir ou diminuir os ataques epilépticos em um paciente. A presente descrição também refere-se a um método para aumentar a exposição a eslicarbazepina em um paciente. A presente descrição também refere-se a um método de preparação de uma composição farmacêutica compreendendo acetato de eslicarbazepina.USE OF A PHARMACEUTICAL COMPOSITION, METHOD FOR PREPARING A PHARMACEUTICAL COMPOSITION, AND USE OF AN EFFECTIVE AMOUNT OF ESLICARBAZEPINE ACETATE. The present disclosure relates to the treatment of various diseases and conditions with eslicarbazepine acetate. The present disclosure also relates to the use of eslicarbazepine acetate in a method for reducing or decreasing epileptic seizures in a patient. The present disclosure also relates to a method for increasing eslicarbazepine exposure in a patient. The present disclosure also relates to a method of preparing a pharmaceutical composition comprising eslicarbazepine acetate.

BRPI0520258-2A 2005-05-06 2005-05-06 use of a pharmaceutical composition, method for preparing a pharmaceutical composition, and use of an effective amount of eslicarbazepine acetate BRPI0520258A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2005/002357 WO2006120501A1 (en) 2005-05-06 2005-05-06 Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use

Publications (1)

Publication Number Publication Date
BRPI0520258A2 true BRPI0520258A2 (en) 2009-09-15

Family

ID=35335795

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0520258-2A BRPI0520258A2 (en) 2005-05-06 2005-05-06 use of a pharmaceutical composition, method for preparing a pharmaceutical composition, and use of an effective amount of eslicarbazepine acetate

Country Status (5)

Country Link
AU (1) AU2005331690C1 (en)
BR (1) BRPI0520258A2 (en)
CA (1) CA2607427C (en)
MX (2) MX366496B (en)
WO (1) WO2006120501A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101217959A (en) * 2005-05-06 2008-07-09 坡特拉有限公司 Eslicarbazepine acetate and methods of use
GB0603008D0 (en) * 2006-02-14 2006-03-29 Portela & Ca Sa Method
GB0700773D0 (en) * 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
WO2008095221A1 (en) 2007-02-07 2008-08-14 Gosforth Centre (Holdings) Pty Ltd Treatment of adhd
US8372431B2 (en) 2007-10-26 2013-02-12 Bial-Portela & C.A., S.A. Pharmaceutical composition comprising licarbazepine acetate
WO2010015029A1 (en) * 2008-08-06 2010-02-11 Gosforth Centre (Holdings) Pty Ltd Compositions and methods for treating psychiatric disorders
CA2769181C (en) 2009-07-27 2017-11-28 Bial-Portela & Ca., S.A. Use of 5h-dibenz / b, f/ azepine-5-carboxamide derivatives for treating fibromyalgia
CA2823512A1 (en) * 2010-12-31 2012-07-05 Bial-Portela & C.A., S.A. Granulates comprising eslicarbazepine acetate
WO2013032351A1 (en) * 2011-08-26 2013-03-07 BIAL - PORTELA & Cª, S.A. Treatments involving eslicarbazepine acetate or eslicarbazepine
GB201306095D0 (en) * 2013-04-04 2013-05-22 Bial Portela & Ca Sa New treatments

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT101732B (en) * 1995-06-30 1997-12-31 Portela & Ca Sa SUBSTITUTED AZEPINES PROCESS FOR THE PREPARATION OF THE PHARMACEUTICAL COMPOSITIONS CONTAINED THEREOF AND USES OF THE NEW COMPOUNDS IN THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS EMPLOYED IN DISEASES OF THE NERVOUS SYSTEM
TW200502222A (en) * 2003-04-02 2005-01-16 Novartis Ag Use of 10-hydroxy-10,11-dihydrocarbamazepine derivatives for the treatment of affective disorders

Also Published As

Publication number Publication date
CA2607427C (en) 2015-11-24
AU2005331690A1 (en) 2006-11-16
CA2607427A1 (en) 2006-11-16
WO2006120501A1 (en) 2006-11-16
MX366496B (en) 2019-07-11
AU2005331690C1 (en) 2013-01-17
MX2007013882A (en) 2008-01-28
AU2005331690B2 (en) 2012-09-20

Similar Documents

Publication Publication Date Title
BRPI0520258A2 (en) use of a pharmaceutical composition, method for preparing a pharmaceutical composition, and use of an effective amount of eslicarbazepine acetate
BRPI0609393B8 (en) uses of an 11-deoxy-prostaglandin compound
EA202091999A3 (en) APPLICATION OF DPP IV INHIBITORS
DOP2007000102A (en) ARILIMIDAZOLONAS AND ARILTRIAZOLONA SUBSTITUTED AS WELL AS ITS USE
BRPI1011031A2 (en) arginine salt of an active agent, pharmaceutically acceptable liquid or gel composition, kit, method for treating a neurological disorder and method for treating or alleviating parkinson's disease in a patient in need thereof.
SG158112A1 (en) Hepatocyte growth factor (hgf) binding proteins
WO2007143098A8 (en) Hepatocyte growth factor (hgf) binding proteins
EA201270221A1 (en) TREATMENT OF CROWN DISEASE WITH LACQUINIMODE
CR9949A (en) 5-LIPOXYGENASE ACTIVATING PROTEIN INHIBITORS (FLAP)
MX2010004494A (en) Use of trkb antibodies for the treatment of respiratory disorders.
EA201300522A1 (en) PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF METABOLIC DISORDERS
BR112014008789A2 (en) prevention and treatment of eye conditions
BRPI0720551A2 (en) compound or a pharmaceutically acceptable salt thereof, and, use thereof, method for treating cancer, processes for preparing a pharmaceutical composition and a compound or a pharmaceutically acceptable salt thereof
NO20083780L (en) Topical composition comprising an antibacterial substance
WO2009132656A3 (en) Crystal structure of human sortilin and uses thereof for identifying ligands to sortilin
BRPI0517701A (en) use of a compound in the preparation of medicines for the treatment of diabetes mellitus
ATE456369T1 (en) FLIBANSERIN FOR THE TREATMENT OF URINARY INCONTINENCE AND ASSOCIATED DISEASES
WO2007138466A3 (en) Pharmaceutical compositions comprising meloxicam and tramadol combination
DOP2007000043A (en) SUBSTITUTED CHROMANOL DERIVATIVES AND THEIR USE
WO2010151755A3 (en) TREATMENT OF INFLAMMATORY DISEASES USING miR-124
BRPI0915862A2 (en) tetrahydrocinoline derivatives, process for their manufacture, pharmaceutical composition comprising them, use thereof and method for the treatment or prophylaxis of diabetes and other diseases
AR055939A1 (en) METHODS TO PREPARE PHARMACEUTICAL COMPOSITIONS THAT INCLUDE ACETATO DE ESLICARBAZEPINA AND METHODS OF USE
BRPI0703970A2 (en) treatment of psychiatric patients with reduced liver function with paliperidone
BRPI1008103A2 (en) "isolated short chain peptide, pharmaceutical composition, compounds, method of preventing or treating diseases, medicament for treating / reducing medical conditions and use of the compounds"
BRPI0607976A2 (en) pharmaceutical composition and use of a composition

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO EM SUA FORMA AUTENTICADA; OU SEGUNDO PARECER DA PROCURADORIA NO 074/93, DEVE CONSTAR UMA DECLARACAO DE VERACIDADE, A QUAL DEVE SER ASSINADA POR UMA PESSOA DEVIDAMENTE AUTORIZADA A REPRESENTAR O INTERESSADO, DEVENDO A MESMA CONSTAR NO INSTRUMENTO DE PROCURACAO, OU NO SEU SUBSTABELECIMENTO.

B25D Requested change of name of applicant approved

Owner name: BIAL - PORTELA AND C.A., S.A. (PT)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]